Validation of the Functional Status II questionnaire in the assessment of extremely-low-birthweight infants

Aim  The increased survival of infants born at extremely low birthweight (ELBW) has been associated with significant morbidity, including higher rates of neurodevelopmental disability. However, formalized testing to evaluate these problems is both time-consuming and costly. The revised Functional Status questionnaire (FS-II) was designed to assess caregivers' perceptions of the functional status of children with chronic diseases.
Method  We evaluated the reliability and validity of the FS-II for ELBW infants at 18 to 22 months corrected age using data from the US Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN). Exploratory factor analyses were conducted using data from the network's first follow-up study of 1080 children born in 1993 to 1994 (508 males, 572 females [53%]), and results were confirmed using data from the next network follow-up of 4022 children born in 1995 to 2000 (1864 males, 2158 females [54%]).
Results  Results suggest that a two-factor solution comprising measures of general health and independence is most appropriate for ELBW infants. These factors differed from those found among chronically ill children, and new, more appropriate scales are presented for screening ELBW survivors. Both scales demonstrated good internal consistency: Cronbach's α=0.87 for general health and α=0.75 for independence. Construct validity of the scales was assessed by comparing mean scores on the scales according to scores on the Bayley Scales of Infant Development, second edition (BSID-II), and medical conditions.
Interpretation  As hypothesized, infants with greater functional impairments according to their BSID-II scores or medical conditions had lower scores on the general health and independence scales, supporting the validity of the scales.     

Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children

Summary. We assessed the reliability and construct validity of the Compatible MRI scale for evaluation of elbows, and compared the diagnostic performance of MRI and radiographs for assessment of these joints. Twenty‐nine MR examinations of elbows from 27 boys with haemophilia A and B [age range, 5–17 years (mean, 11.5)] were independently read by four blinded radiologists on two occasions. Three centres participated in the study: (Toronto, n = 24 examinations; Atlanta, n = 3; Cuiaba, n = 2). The number of previous joint bleeds and severity of haemophilia were reference standard measures. The inter‐reader reliability of MRI scores was substantial (ICC = 0.73) for the additive (A)‐scale and excellent (ICC = 0.83) for the progressive (P)‐scale. The intrareader reliability was excellent for both P‐scores (ICC = 0.91) and A‐scores (ICC = 0.93). The total P‐ and A‐scores correlated poorly (r = 0.36) or moderately (r = 0.54), but positively, with clinical‐laboratory measurements. The total MRI scores demonstrated high accuracy for discrimination of presence or absence of arthropathy [P‐scale, area‐under‐the‐curve (AUC) = 0.94 ± 0.05; A‐scale, AUC = 0.89 ± 0.06], as did the soft tissue scores of both scales (P‐scale, AUC = 0.90 ± 0.06; A‐scale, AUC = 0.86 ± 0.06). Areas‐under‐the‐curve used to discriminate severe disease demonstrated high accuracy for both P‐MRI scores (AUC = 0.83 ± 0.09) and A‐MRI scores (AUC = 0.87 ± 0.09), but non‐diagnostic ability to discriminate mild disease. Similar results were noted for radiographic scales. In conclusion, both MRI scales demonstrated substantial to excellent reliability and accuracy for discrimination of presence/absence of arthropathy, and severe/non‐severe disease, but poor to moderate convergent validity for total scores and non‐diagnostic discriminant validity for mild/non‐mild disease. Compared with radiographic scores, MRI scales did not perform better for discrimination of severity of arthropathy.     

Medical Illustration of Today

The spectrum for the differential diagnosis of jaundice is more limited in the aged than in younger patients. Obstruction is the usual cause. The history is as helpful as biochemical and other investigations in excluding the causes of nonobstructive jaundice.

The first principle in management is to bring the patient to an optimal state for operation by a planned program. Other principles are to define the obstruction at operation, to employ simple measures to overcome it, and to insure a postoperative course free of complication.     

Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients

The efficacy and viral safety of a pasteurized, immunoaffinity-purified procoagulant factor VIII protein (FVIII:C; Monoclate-P) was studied in two multicentre, prospective, open-label trials in 30 previously untreated patients, 18 with severe (< 1% FVIII:C activity), and 12 with moderate (1% to 5% FVIII:C activity) haemophilia A. Clinical assessments, performed at screening and regularly thereafter for 6 to > 24 months (maximum 34 months), showed that none of 24 assessable patients acquired illnesses consistent with monitored transfusion-transmissible diseases. No patients acquired hepatitis B surface antigen, or antibodies against hepatitis B core antigen, hepatitis C, or human immunodeficiency virus. Likewise, no patients acquired treatment-related hepatitis A antibodies or sustained elevations of alanine aminotransferase levels. The safety profile for Monoclate-P is brought about by a multi-step safety system that incorporates viral inactivation (through a combination of immunoaffinity chromatography and pasteurization) plus donor screening, plasma testing, and quality assurance. The inhibitor development rate (13% low titre, 10% high titre) was similar to that reported in the literature for other FVIII concentrates (24% to 52%). The most frequently reported adverse events were related to typical infant and childhood diseases. Monoclate-P was effective in all patients treated according to protocol, except in two, who developed inhibitors.     

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study

BACKGROUND: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. OBJECTIVES: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. PATIENTS/METHODS: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UFH before blood drawing were excluded from the analyses on f-TFPI (n = 226). RESULTS: On admission, no significant differences in sTF levels were observed between SAP and ACS patients. By comparison to patients with stable angina, f-TFPI levels significantly increased in patients with acute unstable angina and further increased in patients presenting with non-ST-elevation myocardial infarction and ST-elevation myocardial infarction (P < 10(-4)). Among the 1669 individuals with a coronary artery disease, 56 died from a cardiovascular cause. In prospective analyses, high sTF levels were independently associated with an increased risk of cardiovascular death in individuals with ACS (fully adjusted hazard ratio associated with one quartile increase = 2.06; 95% confidence interval 1.24-3.45; P = 0.006) but not in those with SAP (hazard ratio = 1.07; 95% confidence interval 0.78-1.46; P = 0.67). In SAP and ACS patients, high f-TFPI levels were not independently associated with an increased risk of cardiovascular death. CONCLUSIONS: Plasma sTF levels were predictive of cardiovascular mortality in individuals with ACS, whereas f-TFPI levels were associated with the severity of myocardial damage on admission but were not independently related to outcome.     

在聚乙氧基辛基苯基醚存在下氯米帕明的电分析特性

在聚乙氧基辛基苯基醚存在下氯米帕明的电分析特性张正奇，陈展光，陈声宗，曾鸽鸣，杨植岗（湖南大学化学化工系，长沙４１００８２）氯米帕明（ｃｌｏｍｉｐｒａｍｉｎｅ，ＣＭＩ）能选择性地抑制中枢神经系统内５－ＨＴ的重吸收，可消除抑郁心境，恢复活力。本品使用安...     

下胸段硬膜外阻滞在单肺通气期间对肺内分流的影响

目的探讨全麻下下胸段硬膜外阻滞对单肺通气期间肺内分流(Qs/Qt)的影响。方法术中需行单肺通气的30例择期开胸手术患者,ASAⅡ～Ⅲ,随机分为全麻组(GA组,n=15),全麻复合下胸段硬膜外组(GE组,n=15)。两组病人分别于麻醉前、双肺通气30min、单肺通气5、15、30min时采动脉血及混合静脉血,行血气分析,并计算出Qs/Qt等。结果两组患者在单肺通气后5、15、30min,Qs/Qt均增加(P<0.01),动脉氧分压(PaO2)较双肺通气时下降(P<0.01)。但在各时间点两组Qs/Qt以及PaO2无显著性差异。结论下胸段硬膜外阻滞对单肺通气期间肺内分流和动脉氧合无明显影响,可安全用于开胸单肺通气患者的麻醉。     

The Ideal Thrombolytic Agent: GISSI-2 and ISIS-3

Streptokinase (SK) and tissue plasminogen activator (alteplase [tPA]) are by far the most intensively studied thrombolytic agents, but only recently a direct head-to-head comparison (GISSI-2 Trial, in which 12,490 patients have been randomized) has become available to the scientific community. This trial, with its international extension (the International tPA/SK Mortality Trial) recruited more than 20,000 patients, showed that the two drugs tested (SK and tPA) were substantially comparable as far as the clinical events were considered. ISIS-3, the largest randomized clinical trial ever performed, compares SK, tPA, and APSAC in a factorial design. Its results will be available before spring, 1991. It is likely that these two studies, if the results will be consistent, will give a definitive answer about comparison among thrombolytic drugs. As a consequence of that achievement, the interest of the scientific community will possibly be directed towards the long-term prevention of the infarct complications, namely ventricular remodeling and infarct expansion or life-threatening arrhythmias.